TABLE 3.
Mean changes in total cholesterol values in relation to IBD treatment
| Baseline | Follow‐up | Change | P for comparison with tofacitinib | |
|---|---|---|---|---|
| Model 1—Unadjusted effects | ||||
| Corticosteroids | 3.95 | 4.84 | 0.89 | <0.001 |
| Anti‐TNFα agents | 4.61 | 4.49 | −0.12 | <0.001 |
| Tofacitinib | 4.69 | 5.25 | 0.55 | |
| Model 2—Effects adjusted for sex, age, BMI, CRP, IBD subtype, disease duration, disease extent and concomitant corticosteroid use at baseline | ||||
| Corticosteroids a | 4.28 | 5.25 | 0.96 | <0.001 |
| Anti‐TNFα agents a | 4.95 | 4.75 | −0.20 | <0.001 |
| Tofacitinib a | 4.92 | 5.50 | 0.58 | |
| Baseline | Follow‐up | Change | P for interaction | |
|---|---|---|---|---|
| Models 3—Effects of tofacitinib treatment in clinically relevant strata | ||||
| Sex | ||||
| Man | 4.79 | 5.32 | 0.54 | 0.298 |
| Woman | 4.61 | 5.18 | 0.56 | |
| Age, years | ||||
| 18 | 4.33 | 4.72 | 0.39 | 0.001 |
| 41.3 | 4.68 | 5.23 | 0.55 | |
| 65 | 5.06 | 5.80 | 0.74 | |
| CRP, mg/L | ||||
| 0.3 | 4.70 | 5.29 | 0.59 | 0.079 |
| 3.4 | 4.68 | 5.25 | 0.57 | |
| 15 | 4.60 | 5.13 | 0.53 | |
| BMI, kg/m2 | ||||
| 18 | 4.61 | 5.11 | 0.50 | 0.149 |
| 24.3 | 4.74 | 5.29 | 0.56 | |
| 30 | 4.85 | 5.46 | 0.61 | |
| Disease duration, years | ||||
| 1 | 4.51 | 5.04 | 0.53 | 0.766 |
| 9 | 4.69 | 5.25 | 0.56 | |
| 17 | 4.88 | 5.46 | 0.59 | |
| Disease extent | ||||
| Proctitis | 4.89 | 5.36 | 0.46 | 0.061 |
| Left‐sided | 4.87 | 5.40 | 0.54 | 0.307 |
| Pancolitis | 4.61 | 5.25 | 0.64 | <0.001 |
| Concomitant corticosteroid use at baseline | ||||
| No | 4.52 | 5.08 | 0.55 | 0.489 |
| Yes | 4.89 | 5.51 | 0.63 | |
a
Mean for patients with “average” sex, age, BMI, CRP, disease duration, disease extent and concomitant steroid use at baseline.